[-] Show simple item record

dc.contributor.authorWeismantel, Davideng
dc.date.issued2001-11eng
dc.description.abstractRecommendations for measuring serum aminotransferase levels before initiating pharmacologic treatment for hypercholesterolemia, after 12 weeks of therapy, and periodically afterward are based on expert opinion. It is not recommended that serum creatine kinase (CK) levels be monitored for elevation indicative of myopathy during cholesterol-lowering therapy. (Grade of recommendation: D, based on expert opinion without explicit critical appraisal)eng
dc.identifier.urihttp://hdl.handle.net/10355/2824eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2001 (MU)eng
dc.relation.ispartofcollectionUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjecthypercholesterolemiaeng
dc.subjectpharmacologic treatmenteng
dc.subjectcreatine kinase (CK)eng
dc.subjectaminotransferaseseng
dc.subject.lcshHypercholesteremiaeng
dc.subject.lcshCardiovascular system -- Diseases -- Treatmenteng
dc.subject.lcshCreatine kinaseeng
dc.subject.lcshCreatine -- Therapeutic useeng
dc.titleWhat laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record